Unicycive Therapeutics Inc (UNCY) — Who Owns This Stock? 13F Breakdown (Q2 2026)

UNCY ranks #5066 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

81 institutions disclose a position in UNCY, but none treat it as a major bet — even Dauntless Investment Group, LLC, its most concentrated holder, allocates just 0.8% of its own portfolio to it.

BlackRock has added to its UNCY position for two straight quarters, increasing it by $6.4M to reach $6.6M today.

Cantor Fitzgerald, L. P. has trimmed its UNCY position for two straight quarters, cutting it by $919.5K while still holding $234.5K.

UNCY is up 2.4% today, and institutions have been net buyers of $22.2M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

UNCY reported a net loss of $35.2M over the trailing twelve months.

• Not yet profitable — net loss of $35.2M over the trailing twelve months
• Net income declined year over year, from -$31.5M to -$35.2M
• Operating cash flow was negative, using $31.3M in cash
• Current ratio of 2.59x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.63x equity — within a conventional range